The Covid-19 pandemic is still ongoing, and Phapros maintains the availability of its products.

JAKARTA, 7 Maret 2022 –

PT Phapros, Tbk, one of the national pharmaceutical companies, continues to strive to maintain the availability of its products even though the trend of Covid-19 transmission is currently decreasing.

The CEO of Phapros, Hadi Kardoko, stated that the two-year Covid-19 pandemic has changed the order and lifestyle of society. "People are now more aware of maintaining their health, so the demand for preventive health products such as food supplements and multivitamins has increased," he said.

The increase in demand for products to prevent the spread of Covid-19 is still being experienced by this stock code emitter, PEHA. "Learning from the experience during the Covid-19 pandemic, we continue to make continuous improvements in various systems that support our business processes, such as supply chain, manufacturing, marketing, and supporting to maintain product availability, especially if there is a surge in cases," he added.

On the other hand, Phapros also synergizes with its subsidiary, PT Lucas Djaja Group, to support the availability of products needed by the community.

"We also synergize with Phapros' subsidiary, PT Lucas Djaja Group, to meet community demand and maintain product availability in the market," explained Hadi.

Previously, since the beginning of the Covid-19 pandemic, Phapros has implemented an agile, adaptive, and innovative policy strategy to remain able to grow amid difficult situations like this. The policy includes shifting the product portfolio from one that relied on the travel sector through one of its flagship products, Antimo, to a greater focus on multivitamin and other products related to the prevention and treatment of Covid-19, optimizing all channels that can be used to improve performance, as well as strengthening research and innovation to meet national needs for Covid-19-related products, both promotive, preventive, and curative.

This strategy has been proven by the launch of several new Covid-19-related products in 2020 and 2021, such as Vitamin C Injection (Ascorin Injection), Vitamin C Effervescent (Merzavit C) through its subsidiary, PT Lucas Djaja Group, non-acidic Vitamin C 500 mg safe for people with stomach acid disorders, as well as Pehavit D3 1000 IU.

"We have launched several new products in 2020 and 2021, especially those related to Covid-19. Not only that, in 2022, there are still around 10 new products that we will launch, both related to Covid-19 and not. For us, strengthening the innovation of new products is the key to survival and growth," concluded Hadi.